Metallic Taste in Cancer Patients Treated with Systemic Therapy

IJpma, Irene; Timmermans, Erik R.; Renken, Remco J.; Horst, ter, Gert; Reyners, Anna K. L.

Published in:
Nutrition and cancer-An international journal

DOI:
10.1080/01635581.2017.1250922

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 05-07-2024
Metallic Taste in Cancer Patients Treated with Systemic Therapy: A Questionnaire-based Study

Irene Ijpma, Erik R. Timmermans, Remco J. Renken, Gert J. Ter Horst & Anna K. L. Reyners


To link to this article: http://dx.doi.org/10.1080/01635581.2017.1250922

© 2017 The Author(s). Published by Taylor & Francis© Irene Ijpma, Erik R. Timmermans, Remco J. Renken, Gert J. Ter Horst, and Anna K. L. Reyners

View supplementary material

Published online: 07 Dec 2016.

Submit your article to this journal

Article views: 185

View related articles

View Crossmark data
Metallic Taste in Cancer Patients Treated with Systemic Therapy: A Questionnaire-based Study

Irene IJpma, Erik R. Timmermans, Remco J. Renken, Gert J. Ter Horst, and Anna K. L. Reyners

ABSTRACT
A metallic taste is reported by cancer patients as a side effect of systemic therapy. Despite the high prevalence, this taste alteration has received limited attention. The present study investigated: 1) the prevalence of metallic taste in cancer patients treated with systemic therapy; 2) possible predictors of metallic taste; and 3) characteristics of metallic taste. A heterogeneous population of 127 cancer patients, who had received systemic treatment in the past year or were still on treatment, completed a questionnaire developed for this study. Fifty-eight of 127 (46%) patients reported taste changes in the preceding week. Of these patients, 20 (34%) reported a metallic taste. Patients treated with chemotherapy, concomitant radiotherapy, as well as targeted therapy reported metallic taste. Women experienced metallic taste more often than men. Patients experiencing a metallic taste also reported more frequently that they were bothered by sour food and that everything tasted bitter. The experience of metallic taste was highly variable among patients. In conclusion, metallic taste is a frequently experienced taste alteration by cancer patients. Patients treated with chemotherapy, concomitant radiotherapy, and targeted therapy are all at risk for this taste alteration. However, not all patients reported this alteration as bothersome.

Introduction
Taste changes are common in cancer patients as a result of systemic therapy. Taste changes have been associated with a decreased appetite, dietary intake, and quality of life (1–7). The taste perception of cancer patients can be absent (ageusia), decreased (hypogeusia), increased (hypergeusia), distorted (dysgeusia), or taste can be perceived without an external stimulus (phantogeusia) (8).

Most studies regarding taste changes in cancer patients have focused on the presence of taste changes in general (yes/no) or investigated changes in the perception of the primary tastes sweet, sour, salty, and bitter. A metallic taste is a typical taste alteration frequently reported by cancer patients (9). A recent review showed a prevalence of metallic taste ranging from 10% to 78% in cancer patients treated with chemotherapy (10). Despite the high prevalence of metallic taste, this taste alteration has received limited attention. A cross-sectional study among patients with various cancer types showed that patients, who reported weight loss since the start of treatment, were more likely to report an increased sensitivity to metallic and salty taste, compared to patients who reported weight gain or no weight change (11). The consequences of metallic taste regarding food intake, food preference, and quality of life are unknown. To the best of our knowledge, no study has focused on metallic taste specifically, so far.

The present study aimed to investigate the prevalence of metallic taste in cancer patients treated with systemic therapy and to explore possible predictors of metallic taste regarding age, gender, treatment type, time since most recent treatment, and factors related to taste changes. Furthermore, characteristics of metallic taste, including the perceived intensity, the duration, and consequences regarding food intake were explored.

Methods
Study Population
Cancer patients who had received systemic treatment in the past year or were still on treatment, with the ability...
to comprehend Dutch (both reading and writing), were eligible for inclusion. Patients were heterogeneous regarding cancer type and treatment. During a time period of 3 wk, all eligible patients were invited to participate during their regular follow-up visit at the Medical Oncology outpatient clinic of the University Medical Center Groningen. Moreover, eligible hospitalized patients were asked to participate during a period of 1 wk. During the 3-wk time period that patients visited the outpatient clinic, all patients were asked to participate at the discretion of their treating physician. Eligible patients admitted to the ward were identified at the discretion of the attending physician. Patients received the questionnaire from the treating physician or nurse during the outpatient visits or from a researcher during hospitalization. The patients completed the questionnaire during the visit of the outpatient clinic or during hospitalization. The study was conducted in accordance with the Dutch regulations for research.

**Questionnaire**

A questionnaire was constructed for the present study, since no Dutch questionnaire was available that addressed our specific research questions. Most questions were based on the English version of a validated chemotherapy-induced taste alteration scale (CiTas) (12). The scale of the Japanese CiTas appeared not to be appropriate for the Dutch population, since no appropriate translation of the English grading (no, slightly, somewhat, quite, and very) could be established. Therefore, the scale was altered in a 4-point scale as used in the questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC), the EORTC QLQ-C30 (1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very much) (13). English questions of the CiTas were translated into Dutch and back to English by the researchers and a bilingual physician. Furthermore, questions concerning the ability to detect taste, food aversions, factors that might affect taste (e.g., dry mouth), and metallic taste were added (8,14,15). Adaptations regarding responding scales were made to make the questionnaire uniform. An initial draft of the questionnaire was reviewed by an experienced panel consisting of five researchers in the field of tasting, a medical oncologist, and a data analyst. Next, the draft of the questionnaire was pilot-tested among 30 cancer patients, heterogeneous in age, cancer type, and treatment, to ensure all questions were clear and were interpreted as intended. Based on this pilot, several questions were added or adapted. For example, the questions regarding trouble keeping food down and dry mouth were added, since several patients came up with these symptoms related to their taste changes. Moreover, examples of certain foods that raise an aversion (such as the question “Sweet food bothers me”) were removed from the questionnaire, as several patients based their answers on the examples of foods instead of the taste.

The finalized 47-item questionnaire consisted of three parts (see Supplementary Material). The first part contained eight questions regarding disease and treatment. The last question of the first part was: “Have you experienced a change in taste since your diagnosis?” When patients ticked the box “yes,” they experienced a change in taste somewhere during their course of the disease. All patients filled out this part. The second part consisted of 30 closed questions regarding taste, smell, appetite, food aversions, and factors associated with taste. This part was only filled out by patients who reported to have taste changes in the preceding week. This time window was used to minimize the relay on memory to assess a recent and precise experienced taste sensation. The last two questions of the second part were: “Have you experienced certain foods to taste differently than before your diagnosis?” and “Have you experienced a continuous taste in your mouth that you did not experience before your diagnosis?” The response options included: blood, bitter, something chemical, something musty, drugs, metallic, sweet, salty, sour, and “other, namely.” Multiple answers were possible. Patients who ticked the box “metallic” for one of these questions or for both questions were defined as experiencing a metallic taste. Only this last category of patients filled out the last part of the questionnaire. This third part contained five statements regarding the intensity, the consequences regarding the ability to eat in general and certain foods, and the evoked sensation (by food products or a continuous sensation) of metallic taste using the same 4-point scale as previously mentioned.

**Statistical Analysis**

Descriptive statistics are presented as mean ± standard deviation or percentages. Multiple logistic regression (forward stepwise likelihood ratio method) was used to investigate the relation between metallic taste and several parameters listed in the following sections. Two models were used. The first model explored the relation between metallic taste and characteristics of patients and treatment. The model included the following parameters: age, gender, treatment type, and time since most recent treatment (N = 58). The second model additionally included the responses regarding taste changes and factors associated with taste changes. Patients who filled out “I do not know” at one or more questions were excluded.
from analysis, resulting in 38 patients included in model 2. As this number of patients is low compared to the number of tested parameters, overfitting may occur. Therefore, a third analysis was used with only significant parameters from model 2 to maximize the sample size. The model included only age, gender, treatment type, time since most recent treatment, and the response on “sour food bothers me,” “fatty food bothers me,” and “everything tastes bitter” (N = 54).

To explore the relation between metallic taste and treatment type, treatments were divided into the following treatment groups: platinum-based chemotherapy, taxane-based chemotherapy, other chemotherapy, hormonal therapy, tyrosine kinase inhibitor therapy, other targeted therapy, and concomitant systemic treatment with radiotherapy. The time since most recent treatment was divided into less than 1 mo ago, between 1 and 3 mo ago, and more than 3 mo ago. Patients who received daily treatment were grouped into the category of most recent treatment less than 1 mo ago. Statistical analyses were performed using SPSS, version 22 (SPSS Inc. Chicago, IL). A two-tailed P-value <0.05 was considered statistically significant.

Results

Characteristics of Study Population

A total of 255 patients were asked to participate in the study. Of these patients, 127 (50%) filled out the questionnaire. The characteristics of the patients are shown in Table 1.

Prevalence of Taste Changes

Of the 127 cancer patients, 79 (62%) reported taste changes since diagnosis. Of these 79 patients, 58 (46% of total) had taste changes in the preceding week.

Of the 127 patients, 20 (16%) patients (5 male, 15 female) reported a metallic taste in their mouth and/or that food had a metallic taste. Thus, 34% of the 58 patients who had taste changes in the preceding week experienced a metallic taste (since only patients who reported to have taste changes in the preceding week filled out the questions regarding metallic taste). Patients treated with chemotherapy, concomitant radiotherapy, as well as targeted therapy reported metallic taste with a prevalence of at least 10% (Table 2). Of all treatments, taxane-based chemotherapy had the highest prevalence of metallic taste (4 out of 9; 44%).

<table>
<thead>
<tr>
<th>Table 1. Characteristics of the patients. Cancer patients (N = 127)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean ± SD 56.8 ± 13.7</td>
</tr>
<tr>
<td>Gender, male N (%) 54 (43)</td>
</tr>
<tr>
<td>Treatment group, N (%)</td>
</tr>
<tr>
<td>Platinum-based CT 27 (21)</td>
</tr>
<tr>
<td>Taxane-based CT 9 (7)</td>
</tr>
<tr>
<td>Other CT 33 (26)</td>
</tr>
<tr>
<td>Hormonal therapy 13 (10)</td>
</tr>
<tr>
<td>TKI treatment 13 (10)</td>
</tr>
<tr>
<td>Other targeted treatment 23 (18)</td>
</tr>
<tr>
<td>Concomitant radiotherapy 9 (7)</td>
</tr>
<tr>
<td>Most recent treatment, N (%)</td>
</tr>
<tr>
<td>&lt; 1 mo ago 109 (86)</td>
</tr>
<tr>
<td>Between 1 and 3 mo ago 8 (6)</td>
</tr>
<tr>
<td>&gt; 3 mo ago 10 (8)</td>
</tr>
<tr>
<td>Number of received CT courses, N (%)</td>
</tr>
<tr>
<td>1 9 (13)</td>
</tr>
<tr>
<td>2 14 (20)</td>
</tr>
<tr>
<td>3 16 (23)</td>
</tr>
<tr>
<td>4 16 (23)</td>
</tr>
<tr>
<td>5 3 (4)</td>
</tr>
<tr>
<td>6 8 (12)</td>
</tr>
<tr>
<td>&gt; 6 3 (4)</td>
</tr>
<tr>
<td>Duration of treatment (HT and TT), N (%)</td>
</tr>
<tr>
<td>&lt; 1 mo 4 (8)</td>
</tr>
<tr>
<td>Between 1 and 3 mo 17 (35)</td>
</tr>
<tr>
<td>&gt; 3 mo 28 (57)</td>
</tr>
</tbody>
</table>

CT, chemotherapy; TKI, tyrosine kinase inhibitors; HT, hormonal therapy; TT, targeted therapy.

Table 2. Prevalence of taste changes and metallic taste across treatment groups.

<table>
<thead>
<tr>
<th>Treatment group (TG)</th>
<th>N</th>
<th>Taste changes since diagnosis N (% of TG)</th>
<th>Taste changes preceding week N (% of TG)</th>
<th>Metallic taste N (% of TG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platinum-based CT</td>
<td>27</td>
<td>20 (74)</td>
<td>12 (44)</td>
<td>4 (15)</td>
</tr>
<tr>
<td>Taxane-based CT</td>
<td>9</td>
<td>7 (78)</td>
<td>6 (67)</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Other CT</td>
<td>33</td>
<td>21 (64)</td>
<td>17 (52)</td>
<td>6 (18)</td>
</tr>
<tr>
<td>Hormonal therapy</td>
<td>13</td>
<td>9 (69)</td>
<td>5 (39)</td>
<td>2 (15)</td>
</tr>
<tr>
<td>TKI treatment</td>
<td>13</td>
<td>7 (54)</td>
<td>7 (54)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Other targeted treatment</td>
<td>23</td>
<td>11 (48)</td>
<td>8 (35)</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Concomitant radiotherapy</td>
<td>9</td>
<td>4 (44)</td>
<td>3 (33)</td>
<td>1 (11)</td>
</tr>
</tbody>
</table>

CT, chemotherapy; TKI, tyrosine kinase inhibitors.

Characteristics of Metallic Taste

Table 3 displays the responses of 19 patients (one patient reporting metallic taste did not fill out the last part of the questionnaire) to the statements concerning the characteristics of metallic taste. A high diversity was found across patients regarding the perceived intensity, the consequences regarding the ability to eat in general or certain foods, the evoked sensation, and the duration. Eight of 19 patients reported that metallic taste was one of the most negative aspects of their taste changes.
Predictors of Metallic Taste

Logistic regression with age, gender, treatment group, and time since most recent treatment as independent variables (N = 58) showed that gender was significantly associated with metallic taste (Table 4). Women reported metallic taste more often than men. The second model (N = 37) showed that patients experiencing a metallic taste reported that they were bothered by sour and fatty foods and that everything tasted bitter, more often (Table 5). In the third model (N = 54), only the aversion to sour foods and the bitter taste remained significant related to metallic taste (Table 6).

Discussion

One-third of all patients with taste changes and 16% of all patients reported metallic taste in this heterogeneous group of cancer patients. Previous studies have shown a prevalence of metallic taste in cancer patients treated with chemotherapy ranging from 10% to 78% (16–22). Also, metallic taste in patients treated with radiotherapy has been reported previously (23). To our knowledge, this is the first study that reports metallic taste in patients receiving targeted therapy.

Metallic taste is a much-discussed topic on cancer patient forums. Some patients who experience metallic taste ask desperately for help on these forums to obtain information regarding suitable management strategies. In the present study, the experience of metallic taste was highly variable across the patients. Metallic taste seems not to be bothersome for all patients.

Cancer patients who experienced metallic taste reported more often that everything tasted bitter. In other studies, “metallic or bitter taste” has been reported as a taste alteration instead of “metallic taste” only. Our data confirm that metallic taste and bitter taste are closely related.

Women reported metallic taste more often than men. Also, previous studies performed in cancer patients found that taste changes were more prevalent in women compared to men (7,11,16), whereas other studies found no gender differences (3,22). A study in 89 lung cancer patients showed that women reported more often stronger sensations, while men reported weaker sensations more frequently (24). Reasons for gender differences regarding taste changes are currently unknown. In general, there is evidence that women have a greater taste and smell sensitivity than men (25,26). Therefore, female cancer patients may be more prone to changes in taste function than men.

The participation rate of fifty percent was quite low in the present study. Patients were asked to participate during regular outpatient visits or hospitalization. Since no
extra time was scheduled for the present study, the recruitment of patients was added to the regular work of the treating physicians and nurses. Moreover, not all outpatient visits were suitable to recruit patients (e.g., after discussing progressive disease).

Patients reporting metallic taste reported that they were bothered by sour and fatty foods, more frequently. However, the association between metallic taste and the aversion to fatty foods needs to be interpreted carefully, since the sample size was small in the logistic model including factors associated with taste changes. Health care professionals can draw attention to the risk of an aversion to these foods to support patients experiencing a metallic taste. The following management strategies can be advised when patients suffer from a metallic taste: the use of plastic utensils; to eat cold or frozen foods; adding strong herbs, spices, sweetener, or acid to foods; eating sweet and sour foods; to use “miracle fruit” supplements; and to rinse with chelating agents (10). The use of sour foods and adding sour taste to foods is in contradiction to the present finding that patients who experienced metallic taste more often reported that they were bothered by sour foods. Future studies are needed to clarify this possible relationship.

Metallic sensations have also been reported as a side effect of drugs (27) and throughout pregnancy (28). Moreover, metallic taste might be elicited by oral yeast infections (29), burning mouth syndrome (30), damage by stapedectomy or anesthesia of the chorda tympani (31,32), artificial sweeteners (33), and dental amalgam fillings (34). These factors may have influenced the prevalence of metallic taste in the current study. However, only patients who experienced taste changes in the preceding week completed the questionnaire with regard to metallic taste and were asked to reflect on new symptoms previously unknown to them. Therefore, the reported metallic taste may be due to drug effects or infection, but not due to the other above-mentioned causes.

In conclusion, metallic taste is a side effect of systemic therapy that is not commonly addressed by health care professionals. However, one-third of all patients with taste changes and 16% of all patients reported metallic taste during their treatment. Patients treated with chemotherapy, concomitant radiotherapy, hormonal therapy, and other targeted therapy are all at risk of experiencing a metallic taste. However, not all patients find this type of taste alteration bothersome.

**Acknowledgments and Funding**

The research was funded by TI Food and Nutrition. All authors drafted, read, and approved the final version of the manuscript.

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**References**


